Clinical Trial Update: A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of nivolumab in combination with cabozantinib in patients with non-clear cell renal cell carcinoma; the trial is currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Collecting Duct Renal Cell Carcinoma
• Fumarate Hydratase-deficient Renal Cell Carcinoma
• Non-clear Cell Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Succinate Dehydrogenase-deficient Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING